These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37143546)

  • 1. XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant.
    Islam MA; Kaifa FH; Chandran D; Bhattacharya M; Chakraborty C; Bhattacharya P; Dhama K
    Front Microbiol; 2023; 14():1154296. PubMed ID: 37143546
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 Sep; 24(9):964-973. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?
    Ngiam JN; Al-Mubaarak A; Maurer-Stroh S; Tambyah PA
    Singapore Med J; 2022 Dec; ():. PubMed ID: 36648003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Surveillance Reveals the Rapid Expansion of the XBB Lineage among Circulating SARS-CoV-2 Omicron Lineages in Southeastern Wisconsin, USA.
    Ramaiah A; Khubbar M; Akinyemi K; Bauer A; Carranza F; Weiner J; Bhattacharyya S; Payne D; Balakrishnan N
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.
    Hussain B; Wu C
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity.
    DeGrasse DC; Black SD
    Cureus; 2023 Jun; 15(6):e40148. PubMed ID: 37313287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
    Nahhas AF; Webster TJ
    Colloids Surf B Biointerfaces; 2024 Jan; 233():113638. PubMed ID: 37995630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the XBB strain of SARS-CoV-2: Competition between variants and impact of reinfection.
    Cheng Z; Lai Y; Jin K; Zhang M; Wang J
    J Theor Biol; 2023 Oct; 574():111611. PubMed ID: 37640233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study.
    Selvavinayagam ST; Karishma SJ; Hemashree K; Yong YK; Suvaithenamudhan S; Rajeshkumar M; Aswathy B; Kalaivani V; Priyanka J; Kumaresan A; Kannan M; Gopalan N; Chandramathi S; Vignesh R; Murugesan A; Anshad AR; Ganesh B; Joseph N; Babu H; Govindaraj S; Larsson M; Kandasamy SL; Palani S; Singh K; Byrareddy SN; Velu V; Shankar EM; Raju S
    Lancet Reg Health Southeast Asia; 2023 Dec; 19():100272. PubMed ID: 38076717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) omicron sub-variants in Bangladesh cause mild COVID-19 and associate with similar antibody responses irrespective of natural infection or vaccination history.
    Lytton SD; Ghosh AK; Bulbul RH; Nasifa T; Mamunur R; Meier C; Landt O; Kaiser M
    Heliyon; 2024 May; 10(10):e31011. PubMed ID: 38770337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant.
    Khan K; Lustig G; Römer C; Reedoy K; Jule Z; Karim F; Ganga Y; Bernstein M; Baig Z; Jackson L; Mahlangu B; Mnguni A; Nzimande A; Stock N; Kekana D; Ntozini B; van Deventer C; Marshall T; Manickchund N; Gosnell BI; Lessells RJ; Karim QA; Abdool Karim SS; Moosa MS; de Oliveira T; von Gottberg A; Wolter N; Neher RA; Sigal A
    Nat Commun; 2023 Dec; 14(1):8078. PubMed ID: 38057313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2023 Sep; 29():e942244. PubMed ID: 37654205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mutations in SARS-CoV-2 recombinant sub-variant XBB.1.16 on the binding affinity with human ACE2 receptor.
    Tariq SS; Zia K; Nur-E-Alam M; Nerukh D; Farafonov VS; Ul-Haq Z
    J Mol Graph Model; 2024 Sep; 131():108813. PubMed ID: 38885553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.
    Sil D; Gautam S; Saxena S; Joshi S; Kumar D; Mehta A; Jindal P; Sharma S; Pandey P; Diksha ; Singh A
    Curr Drug Targets; 2024; 25(8):517-525. PubMed ID: 38726782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of multiplex allele-specific RT-qPCR assays for differentiation of SARS-CoV-2 Omicron subvariants.
    Li J; Cheng R; Bian Z; Niu J; Xia J; Mao G; Liu H; Wu C; Hao C
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):35. PubMed ID: 38183475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.